EVERYONE appreciates a bit of honesty once in a while, right?
It just doesn't often come on-the record from the leader of a well-known business, particularly when the honesty is being critical of the company's own product.
But when you're talking about Eucalyptus CEO Tim Doyle, it seems that he's more than happy to play a straight card.
Recently, the founder of the Australian health technology start-up gave a rather frank assessment of its fertility products, which it will discontinue, to the Australian Financial Review.
In announcing that Eucalyptus will stop selling its fertility and skincare products in stores including Priceline and Woolworths, sacking 10 members of staff in the process and refocusing on selling weight-loss drugs online, he said the brand's fertility products "kind of sucked".
He added that, "We need to be better at making hard choices - I'm focused on the multi-hundred-million-dollar opportunities and not the million-dollar ones."
It's not the first time that Eucalyptus and its group of young executives have been up front and made some interesting calls.
Despite last being valued at $560 million, Doyle has also previously said that in the past, "there were months at a time when we had nearly no revenue because there was no medication".
The above article was sent to subscribers in Pharmacy Daily's issue from 06 May 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 May 25
